Precision medicine innovator Closed Loop Medicine (CLM) appoints Kate Woolland as its new Chief Executive Officer, marking a significant leadership transition as the company enters a commercialization-focused phase.
Woolland, formerly CLM’s Chief Operating Officer, steps into the CEO role with a mandate to scale and deploy the company’s proprietary precision dosing platform through strategic partnerships and IP-led integrations. Her appointment aligns with CLM’s mission to unlock the full value of its unique intellectual property (IP) portfolio, particularly in major therapeutic areas such as hypertension, GLP-1 therapies, and metabolic health.
With over 60 patent filings across 16 families globally, CLM’s technology is designed to extend drug lifecycles, enhance market exclusivity, and improve treatment outcomes through therapy-specific dosing protocols. Its personalized titration approach has shown over 90% patient adherence rates in clinical use—demonstrating strong potential for real-world impact.
“As we enter this new phase, we’re focused on identifying the right partners who can fully leverage our technology to transform patient outcomes at scale,” - Kate Woolland.
Woolland brings a wealth of experience from her roles at ieso Digital Health and PA Consulting, where she led successful product launches and built a healthcare transformation business worth over £10 million annually. Her appointment follows the tenure of Dr. Hakim Yadi, CLM’s founding CEO, whose vision laid the foundation for the company’s IP portfolio and integrated pharma-digital platform.
Chair of the Board, Luba Greenwood, commented “Kate’s commercial focus and understanding of the market will be instrumental in identifying optimal partners for our platform as we move from development to value realization.”
As CEO, Woolland will oversee CLM’s continued efforts to:
- Integrate with pharmaceutical pipelines to enhance branded therapies,
- Drive lifecycle management through differentiated follow-on products,
- Support digital health providers with personalized dosing automation,
- Deliver generic differentiation by enabling improved patient management solutions.
CLM’s next chapter under Woolland’s leadership signals a major step in precision medicine’s commercial evolution—bringing smarter, more personalized treatments to patients worldwide.
